Clinical Trials Logo

Immune System Suppression clinical trials

View clinical trials related to Immune System Suppression.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05655273 Not yet recruiting - Clinical trials for Liver Transplant Rejection

Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients

Start date: June 1, 2023
Phase: Phase 4
Study type: Interventional

Prograf and Envarsus are two different formulations of Tacrolimus which is used as an immunosuppressant in liver transplant (LT) patients. Prograf is currently used as part of the standard immunosuppression regimen for LT recipients at UHN. This study will compare the use of Prograf and Envarsus and their effects on liver and renal function, trough tacrolimus levels, drug-related adverse effects, and patient adherence. Trial design is a pilot randomized trial. The study aims to recruit 40 patients from UHN's LT program and they will be randomized 1:1 to either stay on their current dose of Prograf or be converted to a once-daily equivalent dose of Envarsus. Both groups of patients will be followed for 48 weeks. This study will compare the change from baseline to week 48 in liver and renal function, tacrolimus-related side effects and patient reported outcomes between the two study groups.